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Background: There is little available data regarding the long term follow-up of patients
treated with Sirolimus-eluting stent (SES) on the Unprotected Left Main (ULM)
according to EuroScore, SYNTAX score and GRC.
Methods: All consecutive patients treated with SES implantation for ULM stenosis
between March 2002 and December 2008 were restrospectively assessed for clinical
and angiographic risk. The primary end-point of the study was a composite of major
adverse cardiovascular events (MACE) at 3 years defined as all cause death,
myocardial infarction (MI) and target lesion revascularization (TLR) according to
EuroScore, SYNTAX score and GRC. Secondary endpoints were the individual
components of MACE.
Results: Data on 404 patients treated with SES on the ULM were available for outcome
analysis. The median follow-up period was 1373 days (IQR 205-2209 days). The
patients were classified into low (<22), intermediate (23-33) and high SYNTAX (>34
) groups (118, 142 and 143 patients respectively), low (0-2), intermediate (3-5) and
high EuroScore (6- ) groups (128, 172, 103 patients) and low, intermediate and high
GRS groups (204, 152 and 47 patients). MACE at 3 years were as follows: SYNTAX
low 15.3%, SYNTAX inter 29.6% and SYNTAX high 23.1%, EuroScore low 22.7%,
EuroScore inter 20.9% and EuroScore high 27.2% and GRC low 22.7%, GRC inter
20.9% and GRC high 27.2%. Cardiac-death at 3 years was as follows; SYNTAX low
3.4%, SYNTAX inter 5.6% and SYNTAX high 4.9%, EuroScore low 1.6%, EuroScore
inter 3.5% and EuroScore high 10.7% and GRC low 2.9%, GRC inter 5.3% and GRC
high 10.6%. Non cardiac-death at 3 years was as follows; SYNTAX low 5.1%,
SYNTAX inter 4.2% and SYNTAX high 7.7%, EuroScore low 3.9%, EuroScore inter
3.5% and EuroScore high 11.7% and GRC low 3.9%, GRC inter 4.6% and GRC high
17.0%.
Conclusion: The EuroScore and GRC seem to better predict the outcome compared
to the SYNTAX score in patients undergoing PCI with SES for ULM disease.
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Background: In the setting of moderate LM disease, a severe stenosis of the proximal
Left Anterior Descending (LAD) or Circumflex (CTX) could elevate the measured
LM FFR, and hence increase the probability of a false negative test. In the current
study, we modeled these stenoses, and proposed a resistance-based equation to predict
the true LM FFR irrespective of a concomitant epicardial obstruction.
Methods: In a previously validated in vitro model of the coronary circulation, pressure
and flow were measured in the setting of a moderate LM stenosis. FFR LM-true was
defined as pd/pa in the absence of an epicardial stenosis. With increasing concomitant
stenoses in the LAD or CTX, FFR LM-measured was calculated from pd/pa in the
unobstructed vessel. The equation for FFR LM-predicted = R
micro
/(R
LM
+ R
micro
), where
R
micro
= 1/((1/R
microLAD
) + (1/R
microCTX
)).
Results: 75 proximal epicardial stenoses were created in the setting of a moderate LM
lesion. LM FFR-measured was similar to LM FFR-true 0.75+0.09 vs. 0.74+0.07 (p
0.17) for mild concomitant LAD/CTX stenoses (i.e. FFR >0.75), however, LM FFR-
measured was significantly higher than LM FFR-true, 0.84+0.07 vs. 0.71+0.08,
(p<0.0001) in the case of a more severe epicardial lesion (i.e. FFR < 0.75). FFR LM-
measured had only a moderate correlation with FFR LM-true (r2 = 0.63). In contrast,
using our equation, the calculation of FFR LM-predicted was similar to FFR LM-true
for any stenosis severity, 0.74+0.08 vs. 0.72+0.07 (p 0.11), and had a strong correlation
(r2 = 0.91).
Conclusion: LM FFR appears minimally affected by a mild stenosis in the proximal
LAD or CTX. However, the FFR of the LM can be falsely elevated in the setting of a
moderate-severe stenosis. An equation for FFR LM-predicted may have a stronger
correlation in this setting, and deserves further study.
TCT-48
Very Long Term Clinical Outcomes of Patients with Coronary Bifurcation
Lesions Treated with the Biolimus A9 Coated Dedicated Axxess Stent: Results
from the Prospective, Multicenter AXXESS Plus Trial (Final Report of the
Study)
Eberhard Grube1, Franz-Josef Neumann2, Stefan Verheye3, Alexandre Abizaid4,
Dougal McClean5, Karl E Hauptmann6, Iain Simpson7, Philip MacCarthy8,
Christophe Dubois9, Ralf Mueller10
1University Bonn, Bonn, Germany; 2Herz-Zentrum Bad Krozingen, Bad Krozingen,
Germany; 3AZ Middelheim, Antewerp, Belgium; 4Christchurch Hospital,
Christchurch, New Zealand; 5Institute Dante Pazzanese of Cardiology, Sao Paulo,
Brazil; 6Krankenhaus der Barmherzigen Brueder, Trier, Germany; 7University
Hospital Southampton, Southampton, United Kingdom; 8King’s College Hospital,
London, United Kingdom; 9UZ Gasthuisberg, Leuven, Belgium; 10HELIOS Heart
Center, Siegburg, Germany
Background: Coronary bifurcations lesions remain a challenge in interventional
cardiology, and have been associated with increased adverse event rates and inability
to preserve the side branch (SB) ostium. The Axxess stent is a self-expanding
bifurcation stent which releases Biolimus A9™ (BA9) from an abluminal
biodegradable polymer coating, is conically shaped to conform to the bifurcation
anatomy, and supports the carina while preserving the side branch. Overall, the Axxess
dedicated device demonstrated safety and efficacy for the treatment of complex
bifurcation lesions in the mid-term follow-up (FU); however, the very late outcomes
are still unknown.
Methods: The Axxess Plus trial enrolled 139 patients with single de novo coronary
bifurcation lesions including 78% “true” bifurcation lesions. Of that, 136 patients
received the Axxess stent, and depending on the extent of disease, additional stents
were placed in one or both distal branches – 40% of SB were treated with an additional
drug-eluting stent (DES). All patients were assigned for angiographic FU at 6 months,
and clinical FU was scheduled at annually up to 5 years.
Results: Device success was 93.5%, and in-stent late lumen loss at 6 months (primary
endpoint) was 0.09 mm in the Axxess DES; regarding restenosis, 7.9% of SB treated
with DES presented with recurrence. Overall, target lesion revascularization (TLR)
rate was 7.5% at 6 months, and there were 3 cases of stent thrombosis (2.2%). The
cumulative incidence of major adverse cardiac events (MACE) at 4 years was 19.7%
(23/117) including cumulative incidence of TLR rate of 12.6%. Importantly, there were
no cases of very late stent thrombosis
Conclusion: The dedicated Axxess bifurcation stent demonstrated sustained efficacy
and safety in patients with complex coronary bifurcation lesions. At 4 year clinical FU,
there were 12.6% TLR rate and no occurrence of very late stent thrombosis. The
complete 5-year clinical FU will be presented at the meeting.
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